Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
New England Journal of Medicine2005Vol. 352(23), pp. 2379–2388
Citations Over TimeTop 1% of 2005 papers
Ronald Petersen, Ronald G. Thomas, Michael Grundman, David Bennett, Rachelle S. Doody, Steven H. Ferris, Douglas Galasko, Shelia Jin, Jeffrey Kaye, Allan I. Levey, Eric Pfeiffer, Mary Sano, Christopher H. van Dyck, Leon J. Thal
Abstract
The new england journal of medicine * CI denotes confidence interval. P values were not adjusted for multiple comparisons. In the donepezil group, when corrected for multiple comparisons, the P value at 24 months for all subjects became nonsignificant (P=0.052), and the P value at 36 months for APOE e 4 carriers also became nonsignificant (P=0.078).
Related Papers
- → Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium(2022)24 cited
- → Donepezil for mild cognitive impairment(2006)170 cited
- → Dementia with cerebrovascular disease: the benefits of early treatment(2005)22 cited
- → Drug therapy of dementia in elderly patients. A review(2005)18 cited
- → The efficacy and safety of butylphthalide combined with donepezil in the treatment of vascular dementia: A meta-analysis(2023)